benzinga.comAlto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Dealabout 1 month ago
businesswire.comAlto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial5 months ago
businesswire.comAlto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial5 months ago
businesswire.comAlto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology7 months ago
businesswire.comAlto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology7 months ago
businesswire.comAlto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights8 months ago
prnewswire.comANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm9 months ago
businesswire.comANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm9 months ago
businesswire.comANRO Investors Have Opportunity to Join Alto Neuroscience, Inc. Fraud Investigation with the Schall Law Firm9 months ago
businesswire.comAlto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder9 months ago